Brokers Set Expectations for Aspira Women’s Health Inc.’s FY2023 Earnings (NASDAQ:AWH)

Aspira Women’s Health Inc. (NASDAQ:AWH – Get Rating) – Equities research analysts at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for Aspira Women’s Health in a note issued to investors on Monday, June 6th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($0.32) for the year.

Aspira Women’s Health (NASDAQ:AWH – Get Rating) last issued its earnings results on Wednesday, May 11th. The company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). Aspira Women’s Health had a negative return on equity of 102.03% and a negative net margin of 485.64%. During the same period last year, the business posted ($0.05) earnings per share.

Separately, Zacks Investment Research upgraded Aspira Women’s Health from a “sell” rating to a “buy” rating and set a $0.75 price objective on the stock in a research note on Tuesday, May 17th.

Shares of AWH opened at $0.73 on Thursday. Aspira Women’s Health has a 52 week low of $0.32 and a 52 week high of $6.25. The stock has a 50 day moving average price of $0.72 and a two-hundred day moving average price of $1.16. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.85 and a quick ratio of 4.82.

In other news, CEO Nicole Sandford purchased 98,000 shares of the firm’s stock in a transaction dated Monday, May 16th. The shares were purchased at an average price of $0.76 per share, with a total value of $74,480.00. Following the completion of the acquisition, the chief executive officer now owns 136,160 shares in the company, valued at approximately $103,481.60. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Valerie Barber Palmieri purchased 43,994 shares of the firm’s stock in a transaction dated Monday, May 16th. The stock was purchased at an average cost of $0.57 per share, for a total transaction of $25,076.58. Following the acquisition, the insider now owns 267,088 shares of the company’s stock, valued at approximately $152,240.16. The disclosure for this purchase can be found here. Insiders own 4.50% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in Aspira Women’s Health by 57.3% in the second quarter. Royal Bank of Canada now owns 9,347 shares of the company’s stock valued at $53,000 after acquiring an additional 3,403 shares during the last quarter. Citigroup Inc. increased its stake in Aspira Women’s Health by 58.6% in the third quarter. Citigroup Inc. now owns 9,211 shares of the company’s stock valued at $30,000 after acquiring an additional 3,405 shares during the last quarter. Invesco Ltd. increased its stake in Aspira Women’s Health by 26.7% in the third quarter. Invesco Ltd. now owns 30,504 shares of the company’s stock valued at $99,000 after acquiring an additional 6,434 shares during the last quarter. Balyasny Asset Management LLC bought a new position in Aspira Women’s Health in the third quarter valued at $34,000. Finally, Jump Financial LLC increased its stake in Aspira Women’s Health by 21.4% in the third quarter. Jump Financial LLC now owns 60,800 shares of the company’s stock valued at $198,000 after acquiring an additional 10,700 shares during the last quarter. 54.01% of the stock is currently owned by hedge funds and other institutional investors.

About Aspira Women’s Health (Get Rating)

Aspira Women’s Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer.

See Also

Receive News & Ratings for Aspira Women’s Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aspira Women’s Health and related companies with MarketBeat.com’s FREE daily email newsletter.